HIMS · available-data snapshot
Hims & Hers Health, Inc. (HIMS): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Hims & Hers Health, Inc. (HIMS); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for HIMS?
We do not publish a fair value for Hims & Hers Health, Inc.. What we can say from its filings and market data is below.
What is HIMS's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: growing quickly. Its weakest: balance sheet looks stretched.
- Value · 57 of 100
Cheaper than 57% of Healthcare companies in US
- Price vs worth · 58 of 100
- Quality · 33 of 100
More profitable than 33% of Healthcare companies in US
- Financial health · 20 of 100
Financially stronger than 20% of Healthcare companies in US
- Growth · 84 of 100
Growing faster than 84% of Healthcare companies in US
- Momentum · 23 of 100
Outperformed 23% of Healthcare companies in US over the past year
Confidence: Low confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $28.71
- Market cap
- $6,
699, 594, 752 - 52-week high
- $52.41
- 52-week low
- $13.74
- Currency
- USD
- Exchange
- NYSE
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Hims & Hers Health, Inc. (HIMS) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, HIMS trades at a recent price of $28.71, a market capitalisation of about $6,699,594,752, sitting 39% of the way up its 52-week range ($13.74–$52.41), on the NYSE.
The standard alternative to a DCF is relative valuation — comparing HIMS's trading multiples against a sector benchmark. Here that gives Fwd P/E of 38.9× (richer than the peer median of 17.6×); P/B of 20.7× (richer than the peer median of 7.9×); P/S of 2.6× (cheaper than the peer median of 6.2×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. HIMS shows a price-to-book (P/B) of 20.67 and book value of $1.39 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. HIMS is in a mixed trend, trading -45.2% from its 52-week high. Over the past year the stock is -45.3%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
HIMS vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | HIMS | Peer median | Read |
|---|---|---|---|
| Fwd P/E | 38.9× | 17.6× | richer than |
| P/B | 20.7× | 7.9× | richer than |
| P/S | 2.6× | 6.2× | cheaper than |
What does Hims & Hers Health, Inc. do?
What does it do?
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. It operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector), headquartered in United States. The company employs roughly 2,442 people.
How does it make money?
The business turns $2.6B in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -12.8%), after a 70% gross margin on the products/services it sells. After all costs, taxes and interest, -5.5% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks stretched: carries heavy debt (4.8× equity), may struggle to cover its short-term bills (0.9× current ratio), and is currently lossmaking.
Who at HIMS filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Boughton Soleil | Chief Legal Officer | Open-market sale | $100,576.66 | Form 4 for Boughton Soleil (opens sec.gov in a new tab) | |
| Okupe Oluyemi | Chief Financial Officer | Open-market sale | $59,400.00 | Form 4 for Okupe Oluyemi (opens sec.gov in a new tab) | |
| Boughton Soleil | Chief Legal Officer | Open-market sale | $100,957.37 | Form 4 for Boughton Soleil (opens sec.gov in a new tab) | |
| Okupe Oluyemi | Chief Financial Officer | Option exercise | $70,140.00 | Form 4 for Okupe Oluyemi (opens sec.gov in a new tab) | |
| Okupe Oluyemi | Chief Financial Officer | Open-market sale | $876,846.15 | Form 4 for Okupe Oluyemi (opens sec.gov in a new tab) | |
| Okupe Oluyemi | Chief Financial Officer | Open-market sale | $354,860.66 | Form 4 for Okupe Oluyemi (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.